Volume 11, Issue 1 (1-2025)
Journal of Research in Applied and Basic Medical Sciences 2025, 11(1): 115-124 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Vaddadi M, Syed A B H, V J, Sulthana S, Nightingale F, Gundla P et al . A retrospective study of serous ovarian tumour with IHC correlation: a three-year study. Journal of Research in Applied and Basic Medical Sciences 2025; 11 (1) :115-124
URL: http://ijrabms.umsu.ac.ir/article-1-367-en.html
URL: http://ijrabms.umsu.ac.ir/article-1-367-en.html
Manoja Vaddadi 
, Ali Baqher Hussaini Syed 
, Jyothi V , Shamoon Sulthana * , Florence Nightingale , Priyatham Gundla , Purnima Sirisha Gattim
, Ali Baqher Hussaini Syed , Jyothi V , Shamoon Sulthana * , Florence Nightingale , Priyatham Gundla , Purnima Sirisha Gattim
Assistant Professor, Department of Pathology, Apollo Institute of Medical Science and Research, Jubilee hills, Hyderabad, Telengana, India , dr.kshilpa@rediffmail.com
Abstract: (423 Views)
Background & Aims: Serous ovarian tumors account for 40% of all ovarian cancer cases and remain a major cause of cancer-related mortality in women due to late-stage diagnosis. This retrospective study aimed to analyze the clinicopathological features of serous ovarian tumors and their correlation with immunohistochemical (IHC) markers, including WT-1, CA-125, CK-7, CK-20, and CEA, to improve diagnostic accuracy and prognostic evaluation.
Materials & Methods: The study included pathology data from August 2020 to July 2023, focusing on patients with ovarian neoplasms. Clinical characteristics were correlated with IHC markers.
Results: Results showed that 62% of tumors occurred in women of reproductive age, with abdominal pain being the most common symptom (62%). The majority (88%) of tumors were benign, while 8% were malignant and 4% were borderline. Most tumors (88%) were unilateral, and the predominant tumor size ranged from 6 to 10 cm. High-grade serous carcinomas were identified in two cases, exhibiting Ki-67 labeling indices of 26–50% and >50%, respectively. Ki-67 expression was significantly higher in malignant tumors (50%) compared to borderline tumors (26%) (p < 0.001).
IHC analysis showed strong WT1 nuclear expression, CK7 cytoplasmic expression, and CA125 membrane staining in serous ovarian cancer cases. CK20 and CEA were negative in all cases of serous adenocarcinoma. Malignant tumors exhibited significantly higher Ki-67 expression than borderline tumors.
Conclusion: The study concluded that increasing age, postmenopausal status, bilaterality, and complex tumor morphology were associated with malignancy risk. The use of IHC markers such as WT1, CK7, CK20, CEA, and CA125 remains essential for accurate diagnosis and differentiation of serous ovarian tumors.
Materials & Methods: The study included pathology data from August 2020 to July 2023, focusing on patients with ovarian neoplasms. Clinical characteristics were correlated with IHC markers.
Results: Results showed that 62% of tumors occurred in women of reproductive age, with abdominal pain being the most common symptom (62%). The majority (88%) of tumors were benign, while 8% were malignant and 4% were borderline. Most tumors (88%) were unilateral, and the predominant tumor size ranged from 6 to 10 cm. High-grade serous carcinomas were identified in two cases, exhibiting Ki-67 labeling indices of 26–50% and >50%, respectively. Ki-67 expression was significantly higher in malignant tumors (50%) compared to borderline tumors (26%) (p < 0.001).
IHC analysis showed strong WT1 nuclear expression, CK7 cytoplasmic expression, and CA125 membrane staining in serous ovarian cancer cases. CK20 and CEA were negative in all cases of serous adenocarcinoma. Malignant tumors exhibited significantly higher Ki-67 expression than borderline tumors.
Conclusion: The study concluded that increasing age, postmenopausal status, bilaterality, and complex tumor morphology were associated with malignancy risk. The use of IHC markers such as WT1, CK7, CK20, CEA, and CA125 remains essential for accurate diagnosis and differentiation of serous ovarian tumors.
Type of Study: orginal article |
Subject:
General
References
1. Webb PM, Jordan SJ. Global epidemiology of epithelial ovarian cancer. Nat. Rev. Clin. Oncol 2024;21(5):389-400. [DOI:10.1038/s41571-024-00881-3] [PMID]
2. Ali AT, Al-Ani O, Al-Ani F. Epidemiology and risk factors for ovarian cancer. Prz. Menopauzalny 2023;22(2):93-104. [DOI:10.5114/pm.2023.128661] [PMID] [PMCID]
3. Sumanasekera WK. Epidemiology of ovarian cancer: Risk factors and prevention. Biomed. J. Sci. Tech. Res 2018;11(2). [DOI:10.26717/BJSTR.2018.11.002076]
4. Charkhchi P, Cybulski C, Gronwald J, Wong FO, Narod SA, Akbari MR. CA125 and ovarian cancer: A comprehensive review. Cancers (Basel) 2020;12(12):3730. [DOI:10.3390/cancers12123730] [PMID] [PMCID]
5. Chandra A, Pius C, Nabeel M, Nair M, Vishwanatha JK, Ahmad S, et al. Ovarian cancer: Current status and strategies for improving therapeutic outcomes. Cancer Med 2019;8(16):7018-31. [DOI:10.1002/cam4.2560] [PMID] [PMCID]
6. Rosai J. Rosai and Ackerman's surgical pathology. 9rd. St. Louis: CV Mosby Co.; 2004. vol 2:1649-1736. [Google Scholar]
7. Modepalli N, Venugopal SB. Clinicopathological study of surface epithelial tumours of the ovary: An institutional study. J. Clin. Diagn. Res 2016;10(10):EC01-4. [DOI:10.7860/JCDR/2016/21741.8716] [PMID] [PMCID]
8. Adami HO, Hsieh CC, Lambe M, Trichopoulos D, Leon D, Persson I, et al. Parity, age at first childbirth, and risk of ovarian cancer. Lancet 1994;344(8932):1250-4. [DOI:10.1016/S0140-6736(94)90749-8] [PMID]
9. Hildreth et al. An epidemiological study of ovarian carcinoma ovary. Amer J Epidemiol 1981;114:389-405. [DOI:10.1093/oxfordjournals.aje.a113207] [PMID]
10. Kayastha S. Study of ovarian tumors in Nepal Medical College Teaching Hospital. Nepal Med Coll J 2009;11(3):200-2. [Google Scholar]
11. Rashid S, Sarwar G, Ali A. A clinicopathological study of ovarian cancer. Mother-Child 1998;36:117-25.
12. Jha R, Karki S. Histological pattern of ovarian tumors and their age distribution. Nepal Med Coll J 2008;10(2):81-5. [Google Scholar]
13. Pilli GS, Suneeta KP, Dhaded AV, Yenni VV. Ovarian tumors: a study of 282 cases. JIMA 2002;100(7):420-3. [Google Scholar]
14. Gursan N, Sipal S, Calik M, Gundogdu C. P53, BCL-2, ki-67 li (labeling index) status in benign, proliferative, and malignant ovarian surface epithelial neoplasms. Eurasian J Med 2009;41(1):10-14. [PMID]
15. Ayadi L, Chaabouni S, Khabir A, Amouri H, Makni S, Guermazi M, Frikha M, Boudawara TS. Correlation between immunohistochemical biomarkers expression and prognosis of ovarian carcinomas in Tunisian patients. World J. Oncol 2010;1(3):118. [DOI:10.4021/wjon2010.06.213w] [PMID] [PMCID]
16. Sylvia MT, Kumar S, Dasari P. The expression of immunohistochemical markers estrogen receptor, progesterone receptor, Her-2-neu, p53, and Ki-67 in ovarian epithelial tumors and its correlation with clinicopathologic variables. Indian J Pathol Microbiol 2012;55(1):33. [DOI:10.4103/0377-4929.94852] [PMID]
17. Doubeni CA, Doubeni ARB, Myers AE. Diagnosis and Management of Ovarian Cancer. AFP 2016;93(11):937-44. [Google Scholar]
18. Dilley J, Burnell M, Gentry-Maharaj A, Ryan A, Neophytou C, Apostolidou S, et al. Ovarian cancer symptoms, routes to diagnosis and survival - Population cohort study in the 'no screen' arm of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). Gynecol Oncol 2020;158(2):316-22. [DOI:10.1016/j.ygyno.2020.05.002] [PMID] [PMCID]
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
Contact Information
Address: Urmia University of Medical Sciences, Jahad Ave., Urmia, I.R. Iran. Post code: 57147-83734. P.O. Box. 1138
Email: ijrabms
gmail.com
rabmsumsu.ac.ir
Tel / Fax: +984431937332/+984432240642
